Prenetics Global Limited (NASDAQ:PRE - Free Report) - Research analysts at Sidoti reduced their Q3 2028 earnings estimates for Prenetics Global in a research note issued to investors on Thursday, November 19th. Sidoti analyst A. Hantman now forecasts that the company will earn $0.52 per share for the quarter, down from their previous forecast of $0.60. The consensus estimate for Prenetics Global's current full-year earnings is ($2.36) per share.
Prenetics Global (NASDAQ:PRE - Get Free Report) last issued its quarterly earnings data on Sunday, November 1st. The company reported ($1.45) EPS for the quarter. Prenetics Global had a negative return on equity of 31.73% and a negative net margin of 46.76%. The company had revenue of $64.11 million for the quarter.
PRE has been the subject of a number of other research reports. Lucid Cap Mkts upgraded Prenetics Global to a "strong-buy" rating in a report on Monday, October 12th. Weiss Ratings restated a "sell (d-)" rating on shares of Prenetics Global in a report on Thursday, October 15th. Craig Hallum started coverage on Prenetics Global in a research report on Thursday, September 17th. They set a "buy" rating and a $40.00 price target for the company. Wall Street Zen upgraded Prenetics Global from a "sell" rating to a "hold" rating in a research note on Saturday, August 22nd. Finally, Maxim Group initiated coverage on shares of Prenetics Global in a research report on Monday, October 26th. They set a "buy" rating and a $41.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $36.17.
Read Our Latest Stock Analysis on PRE
Prenetics Global Trading Down 0.4%
PRE opened at $10.31 on Friday. The stock has a market capitalization of $173.93 million, a P/E ratio of -2.03 and a beta of 0.40. Prenetics Global has a 12 month low of $9.13 and a 12 month high of $27.24. The firm's fifty day simple moving average is $19.53 and its 200 day simple moving average is $19.44.
Institutional Investors Weigh In On Prenetics Global
A number of institutional investors have recently made changes to their positions in the company. Virtu Financial LLC acquired a new position in Prenetics Global in the 3rd quarter valued at $252,000. Goldman Sachs Group Inc. acquired a new stake in shares of Prenetics Global during the third quarter worth $253,000. Marshall Wace LLP acquired a new stake in shares of Prenetics Global during the third quarter worth $3,643,000. State Street Corp acquired a new stake in shares of Prenetics Global during the third quarter worth $264,000. Finally, Prospect Capital Advisors LLC bought a new stake in shares of Prenetics Global in the third quarter valued at about $9,279,000. Institutional investors own 25.01% of the company's stock.
Insiders Place Their Bets
In related news, CFO Brian Rosin acquired 5,100 shares of Prenetics Global stock in a transaction on Tuesday, August 25th. The stock was purchased at an average cost of $22.80 per share, with a total value of $116,280.00. Following the completion of the transaction, the chief financial officer directly owned 23,100 shares in the company, valued at $526,680. This trade represents a 28.33% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Danny Sheng Wu Yeung acquired 17,181 shares of the firm's stock in a transaction on Monday, August 24th. The stock was bought at an average price of $21.23 per share, for a total transaction of $364,752.63. Following the completion of the acquisition, the chief executive officer owned 112,416 shares of the company's stock, valued at approximately $2,386,591.68. The trade was a 18.04% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders purchased 40,281 shares of company stock worth $862,453. 7.80% of the stock is owned by company insiders.
Recent Prenetics Global Headlines
Investors following PRE have been watching these headlines:
- Positive Sentiment: Third-quarter revenue rose about 228% year over year to $64.1 million, topping both company guidance and analyst estimates. IM8 revenue grew 266% to $62.9 million, its seventh consecutive record quarter. Prenetics reaffirmed its 2026 revenue outlook of $220–230 million and forecast IM8 revenue of more than $400 million in 2027. Prenetics third-quarter results and guidance
- Neutral Sentiment: B. Riley lowered its price target to $31 from $37 but maintained a Buy rating, leaving a bullish view alongside a reduced valuation target. B. Riley recommendations
- Negative Sentiment: Prenetics’ quarterly loss was wider than expected: EPS was negative $0.93 versus analyst expectations of negative $0.90. More significantly, it raised its expected second-half 2026 adjusted EBITDA loss to $30–35 million from its prior $8–12 million outlook, reflecting increased customer-acquisition investment. This profitability outlook helps explain recent share weakness. Prenetics shares fall on wider loss and lower second-half guidance
About Prenetics Global
(
Get Free Report)
Prenetics Global Limited is a health sciences company focused on consumer wellness and health-related products. Its portfolio includes IM8, a consumer wellness brand offering nutritional supplements, and CircleDNA, a genetic testing service that provides reports on health, wellness and ancestry. The company has also operated clinical genomic testing services and provided COVID-19 testing during the pandemic. Its business has since shifted toward consumer health and wellness. Prenetics was founded in 2014 and is led by co-founder and Chief Executive Officer Danny Yeung.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Prenetics Global, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prenetics Global wasn't on the list.
While Prenetics Global currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.